Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates

Detalles Bibliográficos
Autores principales: Saliba, Antoine N., Kaufmann, Scott H., Stein, Eytan M., Patel, Prapti A., Baer, Maria R., Stock, Wendy, Deininger, Michael, Blum, William, Schiller, Gary J., Olin, Rebecca L., Litzow, Mark R., Lin, Tara L., Ball, Brian J., Boyiadzis, Michael M., Traer, Elie, Odenike, Olatoyosi, Arellano, Martha L., Walker, Alison, Duong, Vu H., Kovacsovics, Tibor, Collins, Robert H., Shoben, Abigail B., Heerema, Nyla A., Foster, Matthew C., Peterson, Kevin L., Schneider, Paula A., Martycz, Molly, Gana, Theophilus J., Rosenberg, Leonard, Marcus, Sonja, Yocum, Ashley O., Chen, Timothy, Stefanos, Mona, Mims, Alice S., Borate, Uma, Burd, Amy, Druker, Brian J., Levine, Ross L., Byrd, John C., Foran, James M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230164/
https://www.ncbi.nlm.nih.gov/pubmed/36315007
http://dx.doi.org/10.1182/bloodadvances.2022008625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230164/
https://www.ncbi.nlm.nih.gov/pubmed/36315007
http://dx.doi.org/10.1182/bloodadvances.2022008625

Ejemplares similares